Search company, investor...

Creative Biomolecules


Merger | Merged

About Creative Biomolecules

Development of regenerative medicines. Merged into Curis, Inc.

Headquarters Location

45 South Street Hopkinton

Massachusetts, 01748,

United States

Missing: Creative Biomolecules's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Creative Biomolecules's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Creative Biomolecules

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Creative Biomolecules is included in 1 Expert Collection, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Creative Biomolecules Frequently Asked Questions (FAQ)

  • What is Creative Biomolecules's latest funding round?

    Creative Biomolecules's latest funding round is Merger.

  • Who are the investors of Creative Biomolecules?

    Investors of Creative Biomolecules include Curis and Domain Associates.

  • Who are Creative Biomolecules's competitors?

    Competitors of Creative Biomolecules include Soleno Therapeutics, Vitae Pharmaceuticals, Advanced Biohealing, Resolvyx Pharmaceuticals, Ironwood Pharmaceuticals and 11 more.

Compare Creative Biomolecules to Competitors

Ribozyme Pharmaceuticals

Ribozyme Pharmaceuticals offers RNA-based pharmaceuticals for human disease


Neuronyx is focused on developing biomedicines by harnessing the therapeutic potential of the human cell.


Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

Aderis Pharmaceuticals

Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.

CoImmune Logo

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

Resolvyx Pharmaceuticals

Resolvyx Pharmaceuticals offers CombinatoRx which is creating new combination medicines that attack disease on multiple fronts

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.